1. Ginsenoside G-Rh2 synergizes with SMI-4a in anti-melanoma activity through autophagic cell death
   Da-lun Lv et al, 2018, Chinese Medicine CrossRef
2. Infrared laser ablation sampling coupled with data independent high resolution UPLC-IM-MS/MS for tissue analysis
   Michael E. Pettit et al, 2018, Analytica Chimica Acta CrossRef
3. PIM inhibitor SMI-4a induces cell apoptosis in B-cell acute lymphocytic leukemia cells via the HO-1-mediated JAK2/STAT3 pathway
   Xingyi Kuang et al, 2019, Life Sciences CrossRef
4. Mutant PIK3CA as a negative predictive biomarker for treatment with a highly selective PIM1 inhibitor in human colon cancer
   Yoon Sun Park et al, 2023, Cancer Biology & Therapy CrossRef
5. Current perspectives on targeting PIM kinases to overcome mechanisms of drug resistance and immune evasion in cancer
   Tom Malone et al, 2020, Pharmacology & Therapeutics CrossRef
6. Pathobiology and Therapeutic Relevance of GSK-3 in Chronic Hematological Malignancies
   Alberto M. Martelli et al, 2022, Cells CrossRef
7. Phytoconstituents and Medicinal Plants for Anticancer Drug Discovery: Computational Identification of Potent Inhibitors of PIM1 Kinase
   Farah Anjum et al, 2021, OMICS: A Journal of Integrative Biology CrossRef
8. Targeting Pim kinases in hematological cancers: molecular and clinical review
   Marcia Bellon et al, 2023, Molecular Cancer CrossRef
9. A New Compound with Increased Antitumor Activity by Cotargeting MEK and Pim-1
   Yanan Li et al, 2020, iScience CrossRef
10. PIM1/STAT3 axis: a potential co-targeted therapeutic approach in triple-negative breast cancer
    Sutapa Mahata et al, 2022, Medical Oncology CrossRef
11. miR24‐2 accelerates progression of liver cancer cells by activating Pim1 through tri‐methylation of Histone H3 on the ninth lysine
    Yuxin Yang et al, 2020, Journal of Cellular and Molecular Medicine CrossRef
12. Pim Kinase Inhibitors Increase Gilteritinib Cytotoxicity in FLT3-ITD Acute Myeloid Leukemia Through GSK-3β Activation and c-Myc and Mcl-1 Proteasomal Degradation
    Jonelle K. Lee et al, 2024, Cancer Research Communications CrossRef
13. Off-target toxicity is a common mechanism of action of cancer drugs undergoing clinical trials
    Ann Lin et al, 2019, Science Translational Medicine CrossRef
14. Therapeutic targeting of PIM KINASE signaling in cancer therapy: Structural and clinical prospects
    Aanchal Rathi et al, 2021, Biochimica et Biophysica Acta (BBA) - General Subjects CrossRef